Work

Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.5567

Authors: Evan P. Pisick, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Eddy Shih-Hsin Yang, Elie G. Dib, Earle Frederick Burgess, Michael Howard Zakem, Nitin Rohatgi, Mehmet Asim Bilen, Sasha L. Warren, Sarah T. Anderson, Andrew Lawrence Rygiel, Richard L. Schilsky

Institutions: Cancer Treatment Centers of America, American Society of Clinical Oncology, Duke Medical Center, University of Alabama at Birmingham, Michigan Cancer Research Consortium, Levine Cancer Institute, Metro Health Hospital, Emory University

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4250031681

Cites:

Cited by: 3

Related to: 10